Main Uses and Therapeutic Applications

Vasopressin, a synthetic form of the naturally occurring antidiuretic hormone (ADH), is primarily utilized to manage specific hemodynamic and fluid balance disorders. Its function revolves around its ability to constrict blood vessels and regulate water retention by the kidneys.

Management of Septic Shock

One of the primary applications of vasopressin is in the treatment of septic shock. In these instances, it is used to increase blood pressure when it remains dangerously low despite other interventions. By stimulating V1 receptors on the smooth muscles of the blood vessels, it induces vasoconstriction, which helps to stabilize blood pressure and improve systemic vascular resistance.

Treatment of Central Diabetes Insipidus

Vasopressin is used to manage central diabetes insipidus, a condition characterized by the body’s inability to produce or release enough antidiuretic hormone. This deficiency leads to excessive thirst and the production of large volumes of very dilute urine. Vasopressin acts on the V2 receptors in the kidneys to increase water reabsorption, thereby reducing urinary output and helping to maintain proper fluid levels in the body.

Gastrointestinal Bleeding

In certain clinical settings, vasopressin may be employed to control bleeding in the digestive tract, such as esophageal varices. Its vasoconstrictive properties help to reduce blood flow to the portal venous system, which can assist in slowing or stopping acute bleeding episodes.

Postoperative Abdominal Distension

Vasopressin is sometimes utilized to prevent or treat postoperative abdominal distension. It promotes muscular contractions within the gastrointestinal tract, aiding in the passage of gas and relieving pressure following surgical procedures.

Benefits and Clinical Goals

The goal of vasopressin therapy is to restore physiological balance in critical or chronic conditions. The primary benefits include:

• Hemodynamic Stability: By increasing vascular resistance, it helps maintain adequate blood pressure to ensure that vital organs receive sufficient oxygen and nutrients.
• Fluid Regulation: It addresses hormonal imbalances that lead to dehydration and electrolyte disturbances by allowing the kidneys to concentrate urine effectively.
• Symptomatic Relief: For chronic conditions like diabetes insipidus, it significantly reduces the frequency of urination and the constant sensation of thirst, improving the patient's daily quality of life.

Eligibility Profile: Who Can and Cannot Use Vasopresina

The eligibility for Vasopresina (Vasopressin) is strictly defined by government regulatory documentation, primarily establishing rules for use in adults for vasodilatory shock.

Category	Eligibility Status (Regulatory Wording)
Absolute Contraindication	Contraindicated in patients with known allergy or hypersensitivity to the active ingredient, 8-L-Arginine Vasopressin, or the excipient chlorobutanol (in applicable formulations).
Condition-Based Exclusion	Should not be used in patients with certain conditions like chronic nephritis with nitrogen retention or patients with advanced arteriosclerosis or coronary thrombosis.
Restricted Use/Caution	Use with caution in patients with a history of vascular disease (e.g., coronary artery disease) or impaired cardiac response, as this may potentially worsen cardiac output.
Pediatric Population	Safety and effectiveness have not been established in pediatric patients for the vasodilatory shock indication. Use in children under 18 years for other indications may be not recommended.
Older Adults (Geriatric)	No safety issues have been identified; however, use requires caution due to a greater likelihood of age-related decreases in organ function.
Pregnancy Eligibility	Use is restricted, as the medication may induce tonic uterine contractions that could threaten the continuation of pregnancy.
Lactation Eligibility	No data is available on the presence of Vasopressin in human milk or its effects on a breastfed infant.

Regulatory documents strictly define eligibility primarily through contraindications and age-related constraints, limiting established use to adults for shock management and classifying pediatric use as not established. The profile requires caution when the medicine is used in patients with cardiovascular or specific renal impairment, ensuring all eligibility criteria are based on official regulatory boundaries.

Interactions with other medicines and products

Official regulatory information regarding Vasopressin (Vasopresina) interactions primarily focuses on pharmacodynamic modifications, as documented in governmental sources like the FDA Prescribing Information.

---

Pharmacodynamic and Exposure Interactions

Interaction Type	Interacting Substances/Classes	Official Interaction Outcome
Pressor Augmentation	Catecholamines, Ganglionic Blocking Agents, SIADH-Inducing Drugs (e.g., SSRIs, Haloperidol)	Increased pressor effect on blood pressure
Effect Attenuation	Drugs Suspected of Causing Diabetes Insipidus (e.g., Lithium, Demeclocycline), Alcohol (Ethanol)	Decreased antidiuretic and/or pressor effect
Effect Prolongation	Indomethacin	May prolong the effect on systemic vascular resistance
Diuretic Interaction	Furosemide	Increases effect on osmolar clearance and urine flow

---

Population and Formulation Constraints

No mandatory timing separation rules are explicitly documented for co-administration. The regulatory label notes that the drug's clearance is increased during the second and third trimesters of pregnancy, which may necessitate a consideration for maintaining the desired therapeutic effect. Furthermore, some formulations containing the preservative Chlorobutanol are officially contraindicated in patients with a known hypersensitivity to that component.

Vasopresina, or Arginine Vasopressin (AVP), functions as a full agonist on two distinct G protein-coupled receptors: the V1 a R and V2 R.

Mechanisms of Vascular Tone and Circulatory Modulation

The molecule activates Vasopressin 1a ( V1 a R) receptors found on the smooth muscle of blood vessels, initiating the Gq signaling cascade to mobilize intracellular calcium. This molecular cascade directly triggers the contraction of vascular smooth muscle cells, leading to an increase in systemic vascular resistance (SVR).

Mechanisms of Renal Fluid Homeostasis ( V2 R Activation)

Simultaneously, the drug activates Vasopressin 2 ( V2 R) receptors in the kidney's collecting ducts, which uses the Gs signaling pathway to increase cAMP. This results in the insertion of Aquaporin-2 water channels into the cell membranes, substantially increasing the reabsorption of free water back into the circulation.

Concentration-Dependent Mechanistic Selectivity

The drug's dual action is concentration-dependent; the V2 R-mediated water conservation mechanism is dominant at low concentrations, while the V1 a R-mediated pressor mechanism requires higher, pharmacological concentrations. This differential selectivity reflects receptor sensitivity across various concentration ranges.

Vasopresina is administered solely through parenteral routes, defined by two distinct administration protocols based on the clinical context. For the critical management of vasodilatory shock, the medicine is administered as a continuous intravenous (IV) infusion.

The concentrated product is not used directly; it must be diluted in specified solutions, such as 0.9% Sodium Chloride or 5% Dextrose in Water, before being introduced via a controlled infusion device. The starting IV dose rate typically ranges from 0.01 to 0.03 units per minute. This rate is titrated by 0.005 units/minute increments over 10 to 15 minute intervals to achieve the desired hemodynamic effect. When discontinuing therapy, the infusion rate must be slowly tapered (weaned) according to a structured protocol to maintain circulatory stability.

Administration for Intermittent Use

The second administration pattern involves Intramuscular (IM) or Subcutaneous (SC) injection for non-critical conditions, such as central diabetes insipidus. For these uses, the standard adult dose is typically 5 to 10 units per injection. This intermittent regimen is repeated as needed, often two or three times daily (every 8 to 12 hours).

Population and Preparation Rules

Regarding specific populations, the effectiveness and safety of Vasopresina for IV infusion have not been established in pediatric patients. However, the IM/SC dose for children is instructed to be proportionately reduced from the adult dose. Additionally, the drug product must be inspected for particulate matter or discoloration prior to administration, and no specific dosage adjustments are officially stated for patients with hepatic or renal impairment in the context of vasodilatory shock.

Research evidence / Overview of studies for Vasopresina

---

Evidence for use in Acute Hypotension Management

Research has actively explored the use of Vasopresina in research examining temporary physiological imbalance during acute hypotension (sudden, severe drops in blood pressure). This area was studied for research exploring short-term symptom changes, primarily within intensive care and operating room settings. The studies were mostly randomized clinical trials (RCTs) that applied in research contexts involving unstable physiological conditions. The trials monitored outcomes related to systemic or functional imbalance by measuring blood pressure stability and the administration of other support medications over defined time intervals.

Findings indicate patterns related to the measured blood pressure levels in certain research settings. The research describes how blood pressure levels evolved in the observed populations during the defined acute time intervals. These findings describe patterns observed in the studies in these acute, short-term scenarios. However, certainty remains low outside of these acute settings. Follow-up durations were limited, and the results apply only to the populations studied, which involved patients with severe acute physiological instability.

---

Evidence for use in Diabetes Insipidus

Vasopresina was evaluated in settings addressing conditions associated with acute or disruptive episodes of water imbalance, specifically Diabetes Insipidus. This research examined outcomes reflecting daily functioning or activity level and monitored physiological strain or stress related to excessive thirst and urination. Studies explored how symptoms evolved in the observed populations, often consisting of observational settings evaluating daily-life functioning or smaller-scale trials.

Data show patterns related to how the body manages fluid and electrolyte levels when Vasopresina is observed in use. Studies report how symptoms evolved in the observed populations, specifically focusing on measured changes in urine output and reported levels of thirst. This evidence contributes to understanding symptom patterns in individuals with this condition.

---

What is still uncertain about Vasopresina

Long-term effects are not fully established regarding the durability of any reported responses or maintenance of changes after continuous use. Evidence is limited for several specific populations, particularly pediatric patients, where comparative evidence is lacking. Findings were mixed in some of the smaller trials, and the research provides context but not individual predictions. Comparative evidence is lacking to fully characterize all measured outcomes against other studied interventions outside of the specific acute situations where it was evaluated in.

Key Studies & References

1. Guidelines for the Use of Vasopressin in Adult Patients with Septic Shock in the ICU

Vasopressin injection should generally be stored in the refrigerator at temperatures between 2 C and 8 C (36 F and 46 F). Do not freeze the medication. Some formulations may be stored at controlled room temperature, typically up to 25 C (77 F), for a specific duration, such as up to 6 or 12 months, depending on the manufacturer's instructions and product type. Always keep the vials in their original protective carton to shield them from light.

Preparation State	Storage Condition	Duration
Undiluted Vial	Refrigerated (2 C-8 C)	Until Expiration Date
Undiluted Vial	Room Temperature (Up to 25 C)	Up to 6 or 12 Months*
Diluted Solution	Room Temperature	Discard after 18 hours
Diluted Solution	Refrigerated	Discard after 24 hours

*Check the specific product label for the exact duration allowed at room temperature.

Dispose of outdated or unneeded vasopressin, including any used needles or syringes, according to the guidance of your healthcare professional, pharmacist, or local regulations for medical waste. Do not dispose of the medication in household trash or pour it down a sink or toilet unless specifically instructed to do so.